Atherosclerosis, the underlying cause of heart attacks, strokes and peripheral vascular disease, is one of the major killers in the world. By 2020 WHO statistics indicate that it will be the most common cause of morbidity and mortality in both the industrialised world and the underdeveloped world. The disease develops slowly over many years in the innermost layer of large and medium-sized arteries (Fig. 1) (Scott, 1995; Ross, 1999; Naumova and Scott, 2000; Glass and Witztum, 2001; Libby, 2001). It does not usually become manifest before the fourth of fifth decade, but then often strikes with devas tating suddenness. Fifty per cent of individuals still die (25 per cent immedi ately) from their first heart attack; and morbidity from coronary heart disease and stroke is very significant. The disease has a profound impact on health care services and on industrial economies. The lesions of atherosclerosis Autopsy studies show that in humans atherosclerosis begins in the first and second decade of life. A similar disease can be produced in experimental animals, where diet and genetics can be manipulated to produce identical lesions. The earliest lesions are fatty streaks. These consist of an accumulation of lipid-engorged macrophages (foam cells) and T and B lymphocytes in the arterial intima. With time, the fatty streaks progress to intermediate lesions, composed of foam cells and smooth muscle cells.
Poor adherence to therapy is one of the main obstacles to treatment effectiveness in schizophrenia. It is the main determinant of relapse, hospitalization, symptom persistence, and poor psychosocial functioning and outcome. Adherence to treatment is affected by various factors related to the disease characteristics, to the patient him- or herself, to the treatment, and to the therapeutic relationship. Some of these factors are modifiable, and both pharmacological and non-pharmacological strategies have been developed for this purpose. This book addresses the different aspects of adherence to treatment in schizophrenia and related disorders in a systematic but easy-to-use manual format. Chapters focus on a full range of issues, including pharmacological and non-pharmacological strategies to enhance adherence and continuity of care, relevant psychological factors, the importance of the patient-doctor relationship, and the need for an alliance with other care-givers. Adherence to Antipsychotics in Schizophrenia will be an invaluable asset for all who are involved in the care of patients with schizophrenia.
This first of the ultimately three-volume Who’s Who in Islamic Studies presents the scholarly world at long last with its own biographical encyclopaedia. Taking as a starting point the inventory of authors from the renowned Index Islamicus, the author, Wolfgang Behn (Berlin), has systematically collected numerous data on the lives and works of the tens of thousands of authors listed in the Index Islamicus from 1665 to 1980. This Biographical Companion will be an indispensable reference tool for the serious student and scholar of Islamic Studies. It enables the user to quickly gain knowledge on the life, work, and professional background of almost every major and minor author, and thus to place each author in his/her proper perspective. A tremendous achievement and a true must for every library.
This publication offers cutting-edge information about basic neurochemical and neuroimmunological research as well as clinical studies of immunological disarrangements and immunological dysfunctions in psychiatric disorders. Psychiatrists and immunologists in the clinic, and researchers in basic sciences will also find this book essential reading. Likewise, it will be relevant to graduate and undergraduate students with a special interest in the neurobiology of psychiatric disorders.
Poor adherence to therapy is one of the main obstacles to treatment effectiveness in schizophrenia. It is the main determinant of relapse, hospitalization, symptom persistence, and poor psychosocial functioning and outcome. Adherence to treatment is affected by various factors related to the disease characteristics, to the patient him- or herself, to the treatment, and to the therapeutic relationship. Some of these factors are modifiable, and both pharmacological and non-pharmacological strategies have been developed for this purpose. This book addresses the different aspects of adherence to treatment in schizophrenia and related disorders in a systematic but easy-to-use manual format. Chapters focus on a full range of issues, including pharmacological and non-pharmacological strategies to enhance adherence and continuity of care, relevant psychological factors, the importance of the patient-doctor relationship, and the need for an alliance with other care-givers. Adherence to Antipsychotics in Schizophrenia will be an invaluable asset for all who are involved in the care of patients with schizophrenia.
The book provides a comprehensive overview of neurodevelopmental disorders comprising motor, speech, cognitive and behavioral dysfunctions. Childhood and adolescent disorders ranging from dyslexia to schizophrenia and including autism, motor disorders and the attention deficit hyperactivity syndrome are presented from the perspectives of genetics, developmental psychology, clinical neurology and psychiatry. A multiprofessional team of experts from the various fields has contributed to this volume, which is aimed at clinicians and researchers alike. The reader will find up to date coverage of the clinically most relevant neurodevelopmental disorders with regard to pathophysiology, clinical presentation and treatment.
Atherosclerosis, the underlying cause of heart attacks, strokes and peripheral vascular disease, is one of the major killers in the world. By 2020 WHO statistics indicate that it will be the most common cause of morbidity and mortality in both the industrialised world and the underdeveloped world. The disease develops slowly over many years in the innermost layer of large and medium-sized arteries (Fig. 1) (Scott, 1995; Ross, 1999; Naumova and Scott, 2000; Glass and Witztum, 2001; Libby, 2001). It does not usually become manifest before the fourth of fifth decade, but then often strikes with devas tating suddenness. Fifty per cent of individuals still die (25 per cent immedi ately) from their first heart attack; and morbidity from coronary heart disease and stroke is very significant. The disease has a profound impact on health care services and on industrial economies. The lesions of atherosclerosis Autopsy studies show that in humans atherosclerosis begins in the first and second decade of life. A similar disease can be produced in experimental animals, where diet and genetics can be manipulated to produce identical lesions. The earliest lesions are fatty streaks. These consist of an accumulation of lipid-engorged macrophages (foam cells) and T and B lymphocytes in the arterial intima. With time, the fatty streaks progress to intermediate lesions, composed of foam cells and smooth muscle cells.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.